Johnson and Johnson: Lower the price for life-saving cancer drug IMBRUVICA
0 have signed. Let’s get to 150,000!
My name is Beth. My mom is fighting a rare cancer that requires her to take a drug called Imbruvica. The drug is highly effective – and extremely expensive. A year’s treatment can cost over $130,000. That’s why I started this petition to demand that Johnson and Johnson (JNJ) stop price-gouging patients who rely on Imbruvica to live.
Upon gaining FDA approval, JNJ raised the price for Imbruvica to over $90 per pill. In the years since, they’ve reported that sales of Imbruvica have soared. Yearly sales of the drug are projected to reach $7.5 billion by 2022. Those are great numbers for Wall Street investors – not so great for patients struggling to pay for the drug to fight their blood cancers.
Critics say the price hikes are happening because companies like Johnson and Johnson hope to rake in the profits before Congress or some regulatory body takes action to stop them. Until then, patients across the U.S. will continue to be taken advantage of by corporations that appear to care nothing for people and only for profit.
We need to stand up and speak out for patients whose lives are at stake.
Please sign and share this petition calling on Johnson and Johnson to immediately lower the price of Imbruvica to match the lowest global market price. It is unconscionable to allow them to continue doing otherwise.
Today: Beth is counting on you
Beth Waxman-Arteta needs your help with “CEO of Johnson and Johnson: Lower the price for life-saving cancer drug IMBRUVICA”. Join Beth and 116,164 supporters today.